Merck appoints new chief ethics and compliance officer
pharmafile | March 30, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Bowles, Holston, MSD, Merck
Merck has announced the appointment of Michael Holston as chief ethics and compliance officer.
Holston is to succeed Richard Bowles, who is retiring from the company after more than 35 years with Merck and the former Schering-Plough. In his new role, Holston, 49, will report directly to Kenneth Frazier, Merck’s chairman and chief executive officer, and will serve on the company’s executive committee.
Frazier said: “We are delighted to welcome Mike as our new chief ethics and compliance officer. His extensive experience managing compliance with healthcare laws across international businesses and his background with Merck and our industry make Mike a terrific leader for our ethics and compliance organisation and a member of our executive committee.
“I also want to thank Rick Bowles for nearly four decades of dedicated service to Merck and Schering-Plough. His strong leadership established the global compliance organization for the combined new company following the merger with Schering-Plough.”
Holston most recently served as executive vice president and general counsel for Hewlett-Packard Company, where he oversaw compliance, government affairs, privacy, ethics operations and legal affairs.
Prior to his role with Hewlett-Packard, Holston was a partner in the litigation practice at Morgan, Lewis & Bockius LLP, where he served as external counsel to Merck on matters such as product litigation, government investigations and compliance with healthcare laws and regulations.
“I’m excited to be joining Merck at this important period of change for the company and the pharmaceutical industry,” said Holston.
Related Content
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …
